Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderate to Severe Chronic Plaque-type Psoriasis”

44 trials

Showing 20 of 44 results

Testing effectiveness (Phase 2)Study completedNCT01490632
What this trial is testing

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Who this might be right for
PsoriasisSkin DiseasesSkin Diseases, Papulosquamous
Eli Lilly and Company 271
Testing effectiveness (Phase 2)Study completedNCT03000075
What this trial is testing

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
AbbVie 182
Large-scale testing (Phase 3)WithdrawnNCT01936688
What this trial is testing

Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Who this might be right for
Plaque-type Psoriasis
Sun Pharmaceutical Industries Limited
Large-scale testing (Phase 3)Study completedNCT03668613
What this trial is testing

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals 84
Large-scale testing (Phase 3)Ended earlyNCT01163253
What this trial is testing

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
Pfizer 2,867
Large-scale testing (Phase 3)Study completedNCT02394561
What this trial is testing

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)

Who this might be right for
Plaque Type Psorisis
Novartis Pharmaceuticals 434
Large-scale testing (Phase 3)Study completedNCT01555125
What this trial is testing

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

Who this might be right for
Moderate to Severe Plaque-type Psoriasis
Novartis Pharmaceuticals 177
Large-scale testing (Phase 3)Study completedNCT01519089
What this trial is testing

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Who this might be right for
Psoriasis
Pfizer 95
Testing effectiveness (Phase 2)Study completedNCT04207801
What this trial is testing

A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis

Who this might be right for
Chronic Plaque-type Psoriasis
Aurigene Discovery Technologies Limited 90
Testing effectiveness (Phase 2)WithdrawnNCT02011269
What this trial is testing

TSO for Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Coronado Biosciences, Inc.
Large-scale testing (Phase 3)Study completedNCT01636687
What this trial is testing

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

Who this might be right for
Plaque-type Psoriasis
Novartis Pharmaceuticals 182
Large-scale testing (Phase 3)Study completedNCT01406938
What this trial is testing

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Who this might be right for
Moderate to Severe Plaque-type Psoriasis
Novartis Pharmaceuticals 967
Testing effectiveness (Phase 2)Study completedNCT00941031
What this trial is testing

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Who this might be right for
Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals 404
Large-scale testing (Phase 3)Study completedNCT02016105
What this trial is testing

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

Who this might be right for
Plaque Type Psoriasis
Sandoz 465
Large-scale testing (Phase 3)Study completedNCT02684370
What this trial is testing

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
AbbVie 560
Large-scale testing (Phase 3)Study completedNCT01891864
What this trial is testing

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel

Who this might be right for
Chronic Stable Plaque Psoriasis
Sandoz 531
Testing effectiveness (Phase 2)Study completedNCT03384745
What this trial is testing

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Who this might be right for
Psoriasis
Bond Avillion 2 Development LP 313
Post-approval studies (Phase 4)Study completedNCT02690701
What this trial is testing

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Chronic Plaque Psoriasis
Novartis Pharmaceuticals 91
Testing effectiveness (Phase 2)Study completedNCT02908347
What this trial is testing

Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

Who this might be right for
PsoriasisPlaque Psoriasis
MetrioPharm AG 46
Early research (Phase 1)Study completedNCT03724292
What this trial is testing

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers

Who this might be right for
Psoriasis
Vitae Pharmaceuticals Inc., an Allergan affiliate 40
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation